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Abstract: The use of genomics to discover novel targets and biomarkers has placed the field 
of oncology at the forefront of precision medicine. First-generation epidermal growth  factor 
receptor (EGFR) inhibitors have transformed the therapeutic landscape of EGFR mutant non-
small-cell lung carcinoma through the genetic stratification of tumors from patients with this 
disease. Somatic EGFR mutations in lung adenocarcinoma are now well established as predic-
tive biomarkers of response and resistance to small-molecule EGFR inhibitors. Despite early 
patient benefit, primary resistance and subsequent tumor progression to first-generation EGFR 
inhibitors are seen in 10%–30% of patients with EGFR mutant non-small-cell lung carcinoma. 
Acquired drug resistance is also inevitable, with patients developing disease progression after 
only 10–13 months of antitumor therapy. This review details strategies pursued in circumventing 
T790M-mediated drug resistance to EGFR inhibitors, which is the most common mechanism 
of acquired resistance, and focuses on the clinical development of second-generation EGFR 
inhibitors, exemplified by afatinib (BIBW2992). We discuss the rationale, mechanism of action, 
clinical efficacy, and toxicity profile of afatinib, including the LUX-Lung studies. We also discuss 
the emergence of third-generation irreversible mutant-selective inhibitors of EGFR and envision 
the future management of EGFR mutant lung adenocarcinoma.
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Introduction
Our biological understanding of the molecular basis of lung cancer progression has been 
accelerated following recent advances in the molecular characterization of the cancer 
genome through the use of high-throughput tumor profiling technologies, such as next-
generation sequencing.1 This use of genomics to discover novel targets and biomarkers 
has put the field of oncology at the forefront of precision medicine.2 In particular, the 
principle of oncogene addiction, in which specific cancer cells are dependent on a certain 
pathogenic oncogene that drives malignant progression, has been exploited with great 
success in the development of targeted therapeutics in lung cancer.3
The epidermal growth factor receptor (EGFR) pathway is one such signaling path-
way that has been targeted for the treatment of patients with EGFR mutant non-small-
cell lung carcinoma (NSCLC). Somatic EGFR mutations in lung cancers are now well 
established as analytically validated and clinically qualified predictive biomarkers of 
response and resistance to small-molecule EGFR tyrosine kinase inhibitors (TKIs). 
Randomized clinical trials have confirmed significant improvements in both response 
rates and progression-free survival (PFS) with both erlotinib (OSI Pharmaceuticals/
Roche) and gef itinib (AstraZeneca) in advanced EGFR mutated NSCLC 
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when  compared with platinum-based chemotherapy, thus 
providing clear proof of concept for an oncogene addiction 
strategy in this setting (Table 1).4–7 The approval of these 
TKIs was a critical milestone for the treatment of NSCLC 
by presenting a model for targeted therapy development 
through the genetic stratification of tumors from patients 
with this disease.
Despite early patient benefit, primary resistance and 
subsequent tumor progression to these first-generation EGFR 
inhibitors are seen in 10%–30% of patients with EGFR mutant 
NSCLC, and acquired drug resistance is ultimately inevitable, 
with patients developing disease progression after a median 
of only 10–13 months of antitumor therapy.4–6,8 Such issues 
have led to increased research on resistance mechanisms to 
EGFR inhibitors and the search for potential solutions to 
overcome such challenges. There are a number of potential 
mechanisms involved in the development of acquired EGFR 
inhibitor resistance. These include the T790M missense 
mutation in exon 20 of the EGFR kinase domain, high-grade 
neuroendocrine (small cell) carcinoma transformation, and 
compensatory escape mechanisms through other critical 
genetic drivers, including c-MET/HGF, HER2, PIK3CA, 
ERK, BRAF, CRKL, and AXL (Figure 1).9
This review details strategies pursued in circumventing 
T790M-mediated drug resistance to EGFR inhibitors, which 
is the most common mechanism of acquired resistance, and 
focuses on the clinical development of second-generation 
EGFR inhibitors, and in particular afatinib (BIBW2992; 
Boehringer Ingelheim). We detail the rationale,  mechanism 
of action, clinical efficacy, and toxicity profile of afatinib, 
including the recent LUX-Lung studies.10,11–15 We also 
briefly discuss the recent development of third-generation 
mutant-selective inhibitors of EGFR and look ahead to the 
future management of EGFR mutant lung adenocarcinoma. 
A detailed discussion on the other mechanisms of resistance 
to EGFR inhibitors is beyond the scope of this review, but the 
reader is directed to several excellent articles.9–17
Circumventing resistance due to 
EGFR T790M mutation
One of the most critical mechanisms for acquired resistance 
is the gatekeeper EGFR T790M missense mutation, which 
is found in approximately 49%–63% of patients who have 
developed resistance to EGFR inhibitors.18,19 Preliminary stud-
ies also indicate that the T790M mutation may play a crucial 
role in primary resistance to first-generation EGFR inhibitors 
because of clonal evolution in tumor cells with preexisting 
T790M mutations.20 Different strategies have been pursued in 
the management of progressive disease after treatment with 
first-generation EGFR TKIs, including monotherapies such 
as dasatinib21 and neratinib,22 as well as the rational combina-
tions of cetuximab plus erlotinib23 and of erlotinib/gefitinib 
plus everolimus.24 To date, the results of these clinical trials 
have, however, been generally disappointing.
A different approach has been the discovery and devel-
opment of the second-generation pan-human epidermal 
growth factor receptor (HER) kinase inhibitors afatinib and 
dacomitinib (PF-00299804; Pfizer; Tables 2 and 3). Both 
compounds are irreversible TKIs with antitumor activity in 
lung cancer cell lines with both sensitive and resistant EGFR 
mutations, including the critical T790M mutation.
Second-generation irreversible  
pan-HER kinase inhibitors
Dacomitinib
Although similar to reversible EGFR inhibitors in competing 
with adenosine triphosphate (ATP) in the kinase domain, 
dacomitinib also covalently binds at the ATP binding cleft on 
Cys773 of EGFR, leading to irreversible blockade of ATP.25 
Dacomitinib was found to be more potent than reversible 
EGFR inhibitors in cell-based assays and had a low off-rate 
compared with reversible inhibitors. Importantly, dacomitinib 
is a pan-HER inhibitor that targets both sensitizing EGFR 
mutants and the secondary EGFR T790M mutant.
Table 1 Summary of clinical trials of commercially available EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy 
in non-small-cell lung carcinoma with activating EGFR mutations
Clinical  
trial
Epidermal growth factor  
receptor tyrosine kinase  
inhibitor
Number of  
patients
Median progression-free  
survival in tyrosine kinase  
inhibitor group (months)
P-value Hazard 
ratio
OPTiMAL52 erlotinib 154 13.1 ,0.0001 0.16
First Signal53 Gefitinib 42 8.4 0.084 0.61
iPASS54 Gefitinib 261 9.5 ,0.0001 0.48
wJTOG340555 Gefitinib 177 9.2 ,0.001 0.48
NeJSG 00256 Gefitinib 200 10.8 ,0.001 0.36
eURTAC57 erlotinib 174 9.4 ,0.0001 0.42
LUX-Lung 311,12 Afatinib 308 13.6 ,0.0001 0.47
Abbreviation: eGFR, epidermal growth fac tor receptor.
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In clinical studies, dacomitinib was shown to be safe and 
generally well-tolerated in Phase I trials, with dose-limiting 
stomatitis, diarrhea, and skin toxicities observed. The maxi-
mum tolerated dose was established at 45 mg daily. However, 
two recent Phase III NSCLC trials failed to meet their pri-
mary objectives.26 Both Phase III trials assessed dacomitinib 
as second- or third-line therapy in molecularly unselected 
patients with advanced NSCLC who had received prior 
chemotherapy. A Study of Dacomitinib (PF-00299804) vs 
Erlotinib in the Treatment of Advanced Non-Small Cell Lung 
Cancer (ARCHER 1009) failed to meet its objective of PFS 
compared with its erlotinib control group, whereas the NCIC 
CTG BR.26 study, in which patients with advanced NSCLC 
had previously received both chemotherapy and an EGFR 
inhibitor, did not meet its primary objective of overall survival 
versus placebo.26,27 A third Phase III study, ARCHER-1050: 
A Study of Dacomitinib vs Gefitinib in 1st-Line Treatment 
of Advanced NSCLC (ARCHER 1050), of treatment-naive 
EGFR mutant NSCLC is currently ongoing and comparing 
dacomitinib to gefitinib, with results due in 2015.26
Afatinib
Rationale and preclinical data
Afatinib is an ATP-competitive inhibitor initially found to 
potently and irreversibly inhibit cysteine residues within the 
catalytic domains of EGFR (Cys797) and HER2 (Cys805), 
EGFR HER2
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Figure 1 eGFR is part of a family of receptor tyrosine kinases (RTKs) that also includes HeR2 (eRBB2), HeR3 (eRBB3) and HeR4 (eRBB4). 
Notes: These RTKs comprise a ligand-binding extracellular domain, a transmembrane link and an intracellular catalytic domain. Binding of growth factors to the extracellular 
domain leads to homo- or hetero-dimerization of the respective receptor, with subsequent activation of RTK activity and regulation of multiple key intracellular signaling 
substrates as shown in the Figure.
Abbreviations: eGFR, epidermal growth factor receptor; HeR, human epidermal growth factor receptor.
Table 2 Summary of clinical trials of eGFR tyrosine kinase inhibitors in development in NSCLC with eGFR mutations
EGFR tyrosine  
kinase inhibitor
Phase Trial  
registration
Targets Trial design
Lapatinib ii NCT00528281 eGFR, HeR2 Single-arm study with pemetrexed
Neratinib ii NCT00266877 eGFR, HeR2 Three-group study
icotinib  
(BPi-2009H)
ii, iii NCT01690390 
NCT01707329 
NCT01516983 
NCT01719536
eGFR Monotherapy and with chemotherapy, radiation  
or other targeted therapies
Afatinib ii, iii Multiple studies Pan-HeR family
Dacomitinib  
(PF00299804)
iii NCT01774721 
NCT01360554
Pan-HeR family Monotherapy versus gefitinib or erlotinib
Poziotinib  
(HM781-36B)
ii NCT01819428 
NCT01718847
Pan-HeR and TeC family First- and second-line monotherapy
AZD9291 i NCT01802632 EGFR mutation specific Monotherapy in previously treated eGFR mutant NSCLC
CO-1686 i, ii NCT01526928 EGFR mutation specific Monotherapy in previously treated eGFR mutant NSCLC
HM61713 i NCT01588145 EGFR mutation specific Monotherapy in previously treated eGFR mutant NSCLC
AP26113 i, ii NCT01449461 Dual ALK and eGFR  
inhibitor
Monotherapy in NSCLC with ALK gene rearrangement  
or mutant eGFR
Abbreviations: eGFR, epidermal growth factor receptor; HeR, human epidermal growth factor receptor; NSCLC, non-small-cell lung carcinoma.
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with half maximal effective concentration values of 0.5 and 
14 nM, respectively.28 In contrast to first-generation revers-
ible EGFR inhibitors, afatinib binds to both EGFR and 
HER2 through covalent bonds, resulting in their irreversible 
blockade and leading to more sustained target modulation. 
By inhibiting HER2 at low nanomolar potency, afatinib 
effectively blocks HER2, the preferred dimerization partner 
of EGFR, and subsequently prevents the formation of HER2 
dimers that contribute to RTK activity and downstream 
pathway signaling. This combined targeting of both EGFR 
and HER2 may be important in overcoming drug resistance 
after treatment with the more specific first-generation EGFR 
inhibitors. Recent preclinical data have now indicated that 
afatinib also irreversibly and potently suppresses the enzy-
matic activity of HER4 (half maximal effective concentra-
tion, 1 nM) in addition to EGFR and HER2.28 Importantly, 
preclinical studies suggest that afatinib is more active than 
first-generation EGFR inhibitors in NSCLC cell lines harbor-
ing T790M mutations,29 whereas in vivo studies have shown 
the antitumor efficacy of afatinib in EGFR L858R/T790M 
double-mutant cancers.29
Afatinib-related toxicities
Several Phase I studies of afatinib have been pursued, assess-
ing different dosing schedules in patients with advanced 
solid tumors. In the Phase I clinical trial of afatinib that 
assessed continuous daily dosing, dose-limiting toxicities 
were observed at dose levels of 30, 40, and 50 mg of afatinib 
daily and comprised grade 3 reversible pneumonitis (n=1) 
and acneiform rash (n=2).30 Overall, an assessment of safety 
data from four afatinib Phase I trials, including this study, 
led to the establishment of the recommended Phase II dose 
of 50 mg afatinib daily.30–32 These afatinib-related toxicities 
mainly included rash, fatigue, and gastrointestinal symptoms 
including diarrhea, stomatitis, mucositis, and nausea.
Proof of concept in eGFR inhibitor-naïve patients: 
LUX-Lung 2 study
This Phase II study evaluated response evaluation criteria in 
solid tumors (RECIST) response rates using two different 
doses (50 or 40 mg daily) of afatinib in EGFR inhibitor-
naïve patients with EGFR mutant NSCLC in both first- and 
second-line settings (Table 3).33 Of 129 patients treated, 
99 received 50 mg afatinib daily, whereas 30 received 40 mg 
of the drug daily. Seventy (66%) of 106 patients harboring the 
two common sensitizing EGFR mutations (exon 19 deletion 
or L858R) achieved objective antitumor responses, whereas 
nine (39%) of 23 patients with less-common mutations LU
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also responded. Overall, afatinib-related toxicities appeared 
less common in patients receiving 40 mg daily of afatinib, 
although there did not appear to be significant differences in 
the efficacy between both doses tested. In view of this better 
risk-to-benefit ratio, the 40 mg dose of afatinib was selected 
for testing in Phase III studies in the early line setting.
First-line afatinib versus chemotherapy in eGFR 
mutant NSCLC: LUX-Lung 3 and 6 studies
The LUX-Lung 3 and 6 studies are randomized Phase III trials 
of afatinib versus up to 6 cycles of standard platinum-doublet 
chemotherapy in patients with EGFR mutated lung adenocar-
cinoma in the first-line treatment setting (Table 3). Although 
the LUX-Lung 3 study recruited globally and randomized 
both Asian and non-Asian patients, the LUX-Lung 6 Phase III 
trial was hosted solely in East Asia.11,12,34 The latter trial was 
conducted because pemetrexed was not routinely available in 
certain countries at the time, including the People’s Republic 
of China, India, and Korea.34 Although LUX-Lung 3 com-
pared afatinib with cisplatin/pemetrexed in 345 patients, 
LUX-Lung 6 compared afatinib with gemcitabine/cisplatin 
in 364 patients. The trials were otherwise identical in design. 
Primary analyses demonstrated an improved PFS with 
afatinib versus chemotherapy in the overall EGFR mutant-
positive population (LUX-Lung 3: hazard ratio [HR], 0.58; 
LUX-Lung 6: HR, 0.28) and specifically benefits in patients 
with common EGFR genotypes (Del19 or L858R: LUX-Lung 
3: HR, 0.47; LUX-Lung 6: HR, 0.25). The US Food and Drug 
Administration and European Medicines Agency have since 
approved afatinib for the first-line treatment of patients with 
advanced NSCLC harboring EGFR mutations.
Although all of the large randomized Phase III trials of 
EGFR TKI versus platinum-doublet chemotherapy have 
demonstrated a marked improvement in PFS for EGFR-RKI 
compared with chemotherapy, none had demonstrated an 
overall survival (OS) advantage because of significant cross-
over between trial groups. Most recently, a pooled analysis of 
mature OS data from the LUX-Lung 3 and 6 trials was pre-
sented.35 This analysis included 631 of 709 patients random-
ized into both trials with common EGFR mutations (Del19, 
n=355; L858R, n=276). A total of 419 patients received 
afatinib and 212 received chemotherapy. OS was significantly 
improved with afatinib versus chemotherapy (median, 27.3 
versus 24.3 months; HR, 0.81 [95% confidence interval 
[CI], 0.66–0.99; P=0.037]). Individual HRs for OS in both 
studies were consistent with the pooled analysis. Among 
patients with EGFR Del19 mutations, HR was 0.59 (95% 
CI, 0.45–0.77; P,0.001), with a median OS of 31.7 months, 
and in those with EGFR L858R mutations, the HR was 1.25 
(95% CI, 0.92–1.71; P=0.160). Updated PFS and safety data 
were consistent with earlier primary reports. Overall, this 
pooled analysis confirmed that first-line afatinib significantly 
improved OS in patients with advanced NSCLC harboring 
common EGFR mutations (Del19 and L858R) compared 
with standard chemotherapy. This was the first EGFR TKI 
to demonstrate this. Afatinib is the only TKI in which such 
a pooled analysis has been undertaken. Moreover, the OS 
pooled analysis indicated the differential activity for afatinib 
by a specific EGFR mutant allele, indicating that for future 
analyses, outcomes of exon 19 deletion patients and L858R 
in studies of EGFR TKIs should not be pooled.
First-line afatinib versus gefitinib: LUX-Lung 7 study
The LUX-Lung 7 study is an ongoing randomized Phase 
IIb global study directly comparing afatinib with gefitinib 
in patients with EGFR mutated lung adenocarcinoma in the 
front-line setting (NCT01466660; Table 3). The co-primary 
endpoints include PFS, time to treatment failure, and OS. 
Given that there are three currently licensed EGFR TKIs in 
Europe (gefitinib, erlotinib, and afatinib), each of which has 
demonstrated a PFS advantage over chemotherapy, this is an 
important study for the future development and registration 
strategy for afatinib and will assist in assessing the optimal 
EGFR TKI to use in the first-line EGFR mutant setting. The 
final data collection date for primary outcome measures is 
estimated in late 2014.
Overcoming acquired resistance: LUX-Lung 1 study
This Phase IIb/III LUX-Lung 1 trial compared the administra-
tion of afatinib versus placebo in a 2:1 ratio in patients with 
advanced lung adenocarcinoma who were previously treated 
with first-line chemotherapy and who had subsequently 
acquired drug resistance to either erlotinib or gefitinib after 
initial benefit (Table 3).36 This study was designed and started 
before routine EGFR genotyping, and thus patients were 
not mandated to harbor EGFR mutations; nevertheless, the 
clinical demographics of patients suggested the likelihood 
of an enriched population for EGFR mutations.
A total of 697 patients were identified, with 585 patients 
randomized to receive afatinib (n=390) or placebo (n=195). 
The primary endpoint of OS (median, 10.8 months in the afa-
tinib group versus 12.0 months in the placebo group; P=0.74) 
was not met. This could be because of the unexpected median 
OS observed in the placebo control group of 12 months, 
which could be a result of most patients in this study receiving 
a number of antitumor treatments after trial  discontinuation 
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(79% in the control group versus 68% in the afatinib group). 
A post hoc analysis of patients who did not receive any 
subsequent antitumor therapies suggested an improved OS 
benefit with afatinib compared with the placebo control group 
(5.8 versus 4.6 months; HR, 0.65). However, the median 
PFS was 3.3 months in the afatinib group compared with 
1.1 months in the placebo group (P,0.0001), and 29 (7%) 
patients achieved a Response Evaluation Criteria In Solid 
Tumors (RECIST) partial response in the afatinib group 
compared with just one patient in the placebo group, provid-
ing clear evidence of afatinib antitumor activity in this EGFR 
inhibitor-resistant population. Furthermore, when limiting the 
PFS analysis to those who met Jackman criteria for acquired 
resistance (36.6% of the trial population),37 the PFS difference 
was 4.5 months versus 1.0 months in favor of the afatinib 
group, suggesting a greater effect of afatinib in subgroups 
with a high likelihood of EGFR mutations.36 Overall, the 
significant improvements in PFS, as well as patient-reported 
symptoms and health-related quality of life observed in this 
clinical study were clinically important findings. There were, 
however, no translational studies reported from this trial to 
validate the activity of afatinib in patients harboring the 
EGFR T790M allele.
Afatinib beyond progression: LUX-Lung 5 study
The LUX-Lung 5 study, a randomized Phase III trial, 
assessed the role of continuing EGFR inhibition alongside 
chemotherapy in likely EGFR mutant NSCLC, after progres-
sion on afatinib, by assessing combination chemotherapy-
afatinib versus mono-chemotherapy alone in patients failing 
afatinib monotherapy (Table 3).38 The primary endpoint was 
PFS. The population of patients recruited to this study was 
similar to that in the LUX-Lung 1 trial: patients with meta-
static NSCLC who had received prior chemotherapy and 
gefitinib/erlotinib, with initial clinical benefit. All patients ini-
tially received 50 mg afatinib daily until disease progression; 
on progression, those who received at least 12 weeks of afa-
tinib were randomized 2:1 to afatinib plus weekly paclitaxel 
(40 mg/day; 80 mg/m2 per week) or investigator’s choice of 
mono-chemotherapy alone.
A total of 202 patients were randomized, including 
134 patients to afatinib and paclitaxel and 68 to chemo-
therapy alone.38 A statistically significant improvement 
in PFS was observed with combination treatment versus 
chemotherapy alone (median, 5.6 versus 2.8 months; HR, 
0.60; 95% CI, 0.43–0.85; P=0.003). The overall response 
rate was also higher in the combination group versus che-
motherapy alone (32.1% versus 13.2%; P=0.005). OS was, 
however, similar in both groups (12.2 versus 12.2 months; 
HR, 1.00; 95% CI, 0.70–1.43; P=0.994). The most commonly 
observed  drug-related toxicities in the combination versus 
 chemotherapy-alone group included diarrhea (53.8% versus 
6.7%), alopecia (32.6% versus 15.0%), and asthenia (27.3% 
versus 28.3%). Overall, this study demonstrated that contin-
ued HER family inhibition with afatinib with the addition 
of paclitaxel significantly improved both PFS and response 
rates versus chemotherapy alone in heavily pretreated NSCLC 
patients with acquired resistance to first-generation EGFR 
inhibitor after disease progression on afatinib monotherapy.
Afatinib activity in the Japanese population:  
LUX-Lung 4 study
A Phase II study was undertaken in Japanese patients with 
advanced lung adenocarcinoma after progression after at least 
12 weeks of prior erlotinib and/or gefitinib (Table 3).10 Sixty-
two patients were treated, including 45 (72.6%) with EGFR 
mutant NSCLC and 51 (82.3%) who had acquired resistance 
to first-generation EGFR inhibitors. There were five (8.1%) 
patients who had RECIST partial response, and two patients 
with secondary T790M mutations (L858R T790M, and dele-
tion in exon 19 T790M) achieved disease stabilization for 9 
months and 1 month, respectively.
Afatinib in squamous NSCLC: LUX-Lung 8 study
In view of the antitumor activity observed in EGFR-wild-
type patients with first-generation EGFR inhibitors, coupled 
with evidence of benefit with other irreversible pan-HER 
inhibitors, this study was initiated to assess the activity of 
afatinib versus erlotinib in squamous subtype NSCLC after 
the failure of at least one prior platinum-based chemotherapy 
(NCT01523587; Table 3). A total of 800 patients are expected 
to be enrolled in this study, with PFS as the primary endpoint. 
This trial has not completed recruitment.
Third-generation irreversible 
mutant-selective EGFR inhibitors
In view of the inevitable development of drug resistance 
despite initial antitumor benefit with first-generation EGFR 
inhibitors, coupled with drug-related toxicities with both first- 
and second-generation EGFR inhibitors, more effective and 
less toxic strategies are needed, including those that target 
the acquired EGFR T790M mutation. Although second-
generation irreversible pan-HER inhibitors such as afatinib 
are also effective in treating EGFR mutant lung cancers, their 
ability to overcome T790M-mediated resistance in the clinic 
is likely to be limited because the concentrations at which 
Pharmacogenomics and Personalized Medicine 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
292
Yap and Popat
these drugs overcome T790M activity preclinically are not 
achievable in humans as a result of dose-limiting toxicities 
related to the nonselective inhibition of wild-type EGFR.39 
These second-generation EGFR inhibitors have also been 
shown to drive drug resistance through the acquisition of 
T790M in both preclinical and clinical settings, suggesting 
low potency against T790M.40,41 As a potential solution, 
afatinib was combined with the EGFR antibody cetuximab 
in a Phase IIB study, which demonstrated an impressive 
response rate of 32% in patients with EGFR mutant lung 
cancers resistant to first-generation EGFR inhibitors. This 
combination regimen was, however, associated with grade 3 
(G3) or worse skin rash in 18% of patients.42
In view of these factors, it is clear that pursuing a more 
potent and selective approach to targeting the EGFR mutant 
lung cancers is a critical need. This has led to the development 
of third-generation EGFR inhibitors that specifically target 
both activating and resistant EGFR mutations, including the 
T790M aberration but not wild-type EGFR. These selective 
EGFR inhibitors include WZ4002, which was the first in 
class to be published but has not proceeded to clinical tri-
als, as well as the oral inhibitors AZD9291 (AstraZeneca),43 
CO-1686 (Clovis),44 and HM61713 (Hanmi Pharmaceutical 
Company Ltd),45 which are currently in clinical trial testing 
(Table 2). The Phase I studies of these latter three drugs 
were recently presented at the 2014 Annual Meeting of the 
American Society of Clinical Oncology.43–45
AZD9291
The Phase I AZD9291 First Time in Patients Ascending 
Dose Study (AURA) involved EGFR mutant NSCLC 
patients who had developed progressive disease to first- and 
second-generation EGFR inhibitors.43 Dose levels explored 
ranged from 20 to 240 mg once a day of AZD9291. Although 
the T790M mutation was not mandated prospectively dur-
ing dose escalation (n=31), the maximum tolerated dose 
expansion required T790M testing with central laboratory 
confirmation (n=201). Pharmacokinetic studies showed a 
terminal half-life of 55 hours. No dose-limiting toxicities 
were observed during the study, and a maximum toler-
ated dose was not established. There was an increase in 
grade 2 adverse events as doses approached 240 mg of 
AZD9291 once daily, including diarrhea, rash, and nausea, 
suggesting some inhibition of wild-type EGFR at higher 
doses of the drug. The overall response rate observed with 
AZD9291 was 53%; an overall response rate of 64% was 
observed in EGFR T790M-positive patients versus 22% in 
EGFR T790M-negative patients. This was an impressive 
response rate considering all patients had developed prior 
disease progression to EGFR inhibitors. The recommended 
Phase II dose was established at 80 mg once daily, based 
on the clinical activity observed in T790M mutant patients 
and an increase in grade 2 toxicities at higher doses of 
AZD9291.
CO-1686
The Phase I study was recently completed in patients with 
EGFR mutant advanced NSCLC previously treated with 
EGFR inhibitors who had a tumor biopsy during screening 
for central EGFR genotyping.44 Eighty-eight patients were 
treated, including 63% who were positive for the EGFR 
T790M mutation. The dose-limiting toxicity rate at all 
doses was less than 33%. Related toxicities included nausea, 
fatigue, and impaired glucose tolerance/hyperglycemia. 
Hyperglycemia was well managed with oral hypoglycemics 
and/or dose reduction. A Phase II  dose of 750 mg twice daily 
was recommended. Forty T790M-positive patients treated 
with doses above 625 mg twice daily were evaluable for 
response, with a 58% partial response rate observed.
HM61713
The Phase I study of HM61713 was conducted in seven 
 centers in Korea and involved 118 patients who were pre-
treated with an EGFR inhibitor who had EGFR mutant 
advanced NSCLC.45 Patients received 75–800 mg of the drug 
daily, with mainly G1–G2 toxicities observed. Two cases of 
dose-limiting toxicities were observed of a G3 drug-induced 
idiosyncratic reaction composed of skin rash and dyspnea, as 
well as G3 raised amylase and G4 lipase. The maximum toler-
ated dose has not been reached, and recruitment to the 800 mg 
daily cohort is ongoing. Of 83 patients treated at the 300 mg 
daily cohort expansion, 15 confirmed partial responses were 
observed, including those with T790M mutations. There were 
no obvious differences in those who had progressed on prior 
EGFR inhibitors within 4 weeks or after 4 weeks or more.
Future perspectives and conclusion
The first-generation EGFR inhibitors gefitinib and erlotinib 
have transformed the treatment landscape of EGFR mutant 
NSCLC and clearly demonstrate the promise of precision 
medicine in molecularly defined tumors through the concept 
of oncogene addiction. However, the emergence of both 
resistant clones, leading to inevitable disease progression, 
and drug-related toxicities resulting from the inhibition 
of wild-type EGFR has limited their effectiveness in this 
population of patients.
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The second-generation pan-HER inhibitors, exemplified 
by afatinib, have shown great promise in patients with EGFR 
mutant NSCLC. A pooled analysis showed that afatinib sig-
nificantly improved OS in patients with advanced NSCLC 
harboring common EGFR mutations (Del 19 and L858R) 
when compared with standard chemotherapy in the first-line 
setting. Importantly, this was the first analysis to show that 
genotype-directed therapy for patients with EGFR mutant 
NSCLC can improve survival. This survival advantage was 
mostly driven by improved OS for the deletion 19 allele, 
a first in the field of EGFR TKI therapy, defining afatinib 
as current standard of care for this specific genotype. 
 Nevertheless, this was only observed in a pooled analysis, 
and not in the respective individual clinical trials. With at 
least two other EGFR TKIs demonstrating a PFS benefit 
over chemotherapy and with the pending head-to-head com-
parisons of first- versus second-generation TKIs (ARCHER 
1050 and LUX-Lung 7 studies), the optimal TKI to choose 
for EGFR mutant NSCLC remains to be established. For 
example, the LUX-Lung 7 randomized trial comparing 
afatinib and gefitinib in patients with EGFR mutated lung 
adenocarcinoma in the first-line setting will yield important 
comparative data to aid decision-making and allow both a 
direct comparison of efficacy as well as drug-related toxici-
ties, which may ultimately limit utility.
Another strategy pursued has been the rational combina-
tion of afatinib with other selective molecular therapeutics. 
For example, the combination trial of cetuximab and afatinib 
has shown promising results, with an overall response rate 
of 29% and a median duration of response of 5.7 months in 
patients with advanced lung adenocarcinoma and acquired 
resistance to erlotinib/gefitinib.46 Importantly, this com-
bination conferred robust and durable clinical responses 
irrespective of T790M status (T790M-positive, 32%, versus 
T790M-negative, 25%; P=0.341), as well as an acceptable 
safety profile.
More recently, third-generation EGFR mutation-specific 
inhibitors have shown potential in circumventing toxici-
ties related to wild-type EGFR and overcoming resistance 
resulting from the acquired T790M mutation. Although large 
cohort expansions embedded within Phase I studies have only 
just been completed with these inhibitors, high response rates 
exceeding 50% in patients who have progressed on first- and 
second-generation EGFR inhibitors have demonstrated their 
promise as effective and well-tolerated drugs.43
There have also been studies that indicate that T790M 
clones preexist in a proportion of EGFR mutant can-
cers before EGFR inhibitor therapy, although the actual 
prevalence remains unclear because of varying sensitivities 
of the assays used.47 These data have important implications 
for determining which space these third-generation EGFR 
inhibitors should occupy in the increasingly busy EGFR 
mutant NSCLC therapeutic landscape. These third-generation 
EGFR inhibitors have been shown to potently block single 
activating mutant forms of EGFR in cell line xenograft and 
human EGFR transgenic mouse models.39,48 It will be impor-
tant to assess whether these preclinical data will translate into 
clinical benefit in treatment-naïve patients and whether there 
will be a delay in the time to the development of acquired 
resistance observed with first-generation EGFR inhibitors, 
thus suggesting the potential to improve PFS in such patients. 
Ultimately, these EGFR mutation-specific third-generation 
inhibitors should be assessed in the first-line setting in 
patients with EGFR mutant NSCLC, as they potently inhibit 
sensitizing EGFR mutations similarly to the T790M allele, 
suggesting the potential for increased survival benefit. There 
are also in vitro data that suggest the potential to inhibit the 
kinase activity of both HER2 and HER4.39
In view of the highly selective nature of these third-
generation EGFR inhibitors, it is likely that drug resistance 
will develop through potential compensatory mechanisms 
that will need to be identified. Preclinical studies have sug-
gested that a direct mutation of cysteine 797, which results in 
acquired resistance to such irreversible inhibitors, may play an 
important role.39 Other key signaling networks may also pro-
vide escape pathways through non-EGFR-related resistance 
mechanisms, such as the insulin-like growth factor receptor, 
mitogen-activated protein kinase, and phosphatidylinositol-3-
kinase–AKT pathways.49,50 In view of this potential for differ-
ent compensatory resistance mechanisms, coupled with their 
mild safety profiles, these inhibitors may ultimately represent 
an ideal partner for combination regimens with chemotherapy, 
targeted therapy, and immunotherapies.
These are exciting times in the treatment of EGFR mutant 
lung cancer, with an armamentarium of antitumor agents now 
available for use. In the future, the optimal sequencing of 
these different EGFR inhibitors will need to be determined 
for maximal benefit to patients. In addition, strategies to 
identify potential escape mechanisms will be critical to direct 
the sequential application of drugs, depending on the under-
lying resistance mechanism. This may involve the molecular 
characterization of sequential tumor biopsies or surrogate 
tissue, such as circulating plasma DNA or circulating tumor 
cells.51 Only through such modern approaches will we truly 
achieve precision and individualized medicine for patients 
with EGFR mutant NSCLC.
Pharmacogenomics and Personalized Medicine 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
294
Yap and Popat
Acknowledgment
SP and TAY acknowledge National Health Service funding 
to the National Institute for Health Research Biomedical 
Research Centre.
Disclosure
TAY is funded by the National Institute for Health Research 
and the Academy of Medical Sciences. SP is a noncompen-
sated consultant to AstraZeneca, Boehringer Ingelheim, 
Clovis, Lilly, and Roche.
References
 1. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer 
genomes through second-generation sequencing. Nat Rev Genet. 
2010;11(10):685–696.
 2. de Bono JS, Ashworth A. Translating cancer research into targeted 
therapeutics. Nature. 2010;467(7315):543–549.
 3. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the 
future of early anticancer drug development. Nat Rev Cancer. 
2010;10(7):514–523.
 4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel 
in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947–957.
 5. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-
cell lung cancer harbouring mutations of the epidermal growth factor 
receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet 
Oncol. 2010;11(2):121–128.
 6. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
 7. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in 
 collaboration with Groupe Français de Pneumo-Cancérologie and Associ-
azione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy 
as first-line treatment for European patients with advanced EGFR mutation-
positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, 
randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
 8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line 
treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, 
randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
 9. Sacher AG, Jänne PA, Oxnard GR. Management of acquired resistance 
to epidermal growth factor receptor kinase inhibitors in patients with 
advanced non-small cell lung cancer. Cancer. 2014;120(15):2289–2298.
 10. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of 
afatinib in patients with advanced non-small-cell lung cancer who 
progressed during prior treatment with erlotinib, gefitinib, or both. 
J Clin Oncol. 2013;31(27):3335–3341.
 11. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life 
in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed 
in patients with advanced lung adenocarcinoma with EGFR mutations. 
J Clin Oncol. 2013;31(27):3342–3350.
 12. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or 
cisplatin plus pemetrexed in patients with metastatic lung adenocarci-
noma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.
 13. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients 
with advanced, metastatic non-small-cell lung cancer after failure of erlo-
tinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 
1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528–538.
 14. Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit 
of afatinib in advanced non-small-cell lung cancer patients previously 
treated with erlotinib or gefitinib: results of a randomized phase IIb/III 
trial (LUX-Lung 1). J Thorac Oncol. 2013;8(2):229–237.
 15. Schuler MH, Planchard D, Yang JCH, et al. Interim analysis of afatinib 
monotherapy in patients with metastatic NSCLC progressing after 
chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus 
paclitaxel versus investigator’s choice chemotherapy following progres-
sion on afatinib monotherapy. Presented at: 2012 Annual Meeting of 
the American Society of Clinical Oncology; 2012; Chicago, IL.
 16. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. 
New strategies in overcoming acquired resistance to epidermal growth 
factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer 
Res. 2011;17(17):5530–5537.
 17. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-
 mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11): 
760–774.
 18. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients 
with acquired resistance to EGFR inhibitors and enhanced detection 
of the T790M mutation using a locked nucleic acid-based assay. Clin 
Cancer Res. 2011;17(5):1169–1180.
 19. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at 
the time of acquired resistance to EGFR-TKI therapy in 155 patients with 
EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
 20. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of muta-
tions in EGFR in circulating lung-cancer cells. N Engl J Med. 
2008;359(4):366–377.
 21. Johnson ML, Riely GJ, Rizvi NA, et al. Phase II trial of dasatinib for 
patients with acquired resistance to treatment with the epidermal growth 
factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac 
Oncol. 2011;6(6):1128–1131.
 22. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-
ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in 
patients with advanced non-small-cell lung cancer. J Clin Oncol. 
2010;28(18):3076–3083.
 23. Janjigian YY, Azzoli CG, Krug LM, et al. Phase I/II trial of cetuximab 
and erlotinib in patients with lung adenocarcinoma and acquired resis-
tance to erlotinib. Clin Cancer Res. 2011;17(8):2521–2527.
 24. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinu-
ation and reinitiation of erlotinib or gefitinib in patients with acquired 
resistance to erlotinib or gefitinib followed by the addition of everoli-
mus. Clin Cancer Res. 2007;13(17):5150–5155.
 25. Carpenter RL, Lo HW. Dacomitinib, an emerging HER-tar-
geted therapy for non-small cell lung cancer. J Thorac Dis. 
2012;4(6):639–642.
 26. Pfizer Inc. Pfizer announces top-line results from two phase 3 trials of 
dacomitinib in patients with refractory advanced non-small cell lung 
cancer. Available from: http://www.pfizer.com/news/press-release/
press-release-detail/pfizer_announces_top_line_results_from_two_
phase_3_trials_of_dacomitinib_in_patients_with_refractory_
advanced_non_small_cell_lung_cancer. Accessed: July 1, 2014.
 27. Ellis PM, Liu G, Millward M, et al. NCIC CTG BR.26: A phase III 
randomized, double blind, placebo controlled trial of dacomitinib ver-
sus placebo in patients with advanced/metastatic non-small cell lung 
cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. 
Presented at: 2014 Annual Meeting of the American Society of Clinical 
Oncology; 2014; Chicago, IL.
 28. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular 
activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. 
J Pharmacol Exp Ther. 2012;343(2):342–350.
 29. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible 
EGFR/HER2 inhibitor highly effective in preclinical lung cancer 
models. Oncogene. 2008;27(34):4702–4711.
 30. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR 
and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid 
tumors. J Clin Oncol. 2010;28(25):3965–3972.
 31. Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation 
study of BIBW 2992, an irreversible dual inhibitor of epidermal growth 
factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week 
on, 2-week off schedule in patients with advanced solid tumours. Br J 
Cancer. 2008;98(1):80–85.
Pharmacogenomics and Personalized Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journal
Pharmacogenomics and Personalized Medicine is an international, peer-
reviewed, open access journal characterizing the influence of genotype 
on pharmacology leading to the development of personalized treatment 
programs and individualized drug selection for improved safety, efficacy 
and sustainability. This journal is indexed on the American Chemical 
Society’s Chemical Abstracts Service (CAS). The manuscript manage-
ment system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
295
Next generation of eGFR inhibitors in NSCLC
 32. Yap TA, Popat S. The role of afatinib in the management of non-small 
cell lung carcinoma. Expert Opin Drug Metab Toxicol. 2013;9(11): 
1529–1539.
 33. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocar-
cinoma and epidermal growth factor receptor mutations (LUX-Lung 2): 
a phase 2 trial. Lancet Oncol. 2012;13(5):539–548.
 34. Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: A randomized, open-label, 
phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as 
first-line treatment for Asian patients (pts) with EGFR mutation-positive 
(EGFR M) advanced adenocarcinoma of the lung. Presented at: 2013 
Annual Meeting of the American Society of Clinical Oncology; 2013; 
Chicago, IL.
 35. Yang JC, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients 
(pts) with advanced non-small cell lung cancer (NSCLC) harboring 
common (Del19/L858R) epidermal growth factor receptor muta-
tions (EGFR mut): Pooled analysis of two large open-label phase III 
studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing 
 afatinib with chemotherapy (CT). Presented at: 2014 Annual Meeting 
of the American Society of Clinical Oncology; 2014; Chicago, IL.
 36. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for 
patients with advanced, metastatic non-small-cell lung cancer after 
failure of erlotinib, gefitinib, or both, and one or two lines of chemo-
therapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 
2012;13(5):528–538.
 37. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resis-
tance to epidermal growth factor receptor tyrosine kinase inhibitors in 
non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357–360.
 38. Schuler MH, Yang CH, Park K, et al. Continuation of afatinib beyond 
progression: Results of a randomized, open-label, phase III trial of afa-
tanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) 
in patients (pts) with metastatic non-small cell lung cancer (NSCLC) 
progressed on erlotinib/gefitinib (E/G) and afatanib – LUX-Lung 5 
(LL5). Presented at: 2014 Annual Meeting of the American Society of 
Clinical Oncology; 2014; Chicago, IL.
 39. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible 
EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors 
in lung cancer. Cancer Discov. Epub June 3, 2014.
 40. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for 
EGFR-mutant non-small cell lung cancer with evolutionary cancer 
modeling. Sci Transl Med. 2011;3(90):90ra59.
 41. Kim Y, Ko J, Cui Z, et al. The EGFR T790M mutation in acquired 
resistance to an irreversible second-generation EGFR inhibitor. Mol 
Cancer Ther. 2012;11(3):784–791.
 42. Janjigian YY, Groen HJ, Horn L, et al. Activity and tolerability of afa-
tinib (BIBW 2992) and cetuximab in NSCLC patients with acquired 
resistance to erlotinib or gefitinib. Presented at: 2011 Annual Meeting 
of the American Society of Clinical Oncology; 2011; Chicago, IL.
 43. Janne PA, Ramalingam SS, Yang JC, et al. Clinical activity of the 
mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR 
inhibitor–resistant non-small cell lung cancer (NSCLC). Presented at: 
2014 Annual Meeting of the American Society of Clinical Oncology; 
2014; Chicago, IL.
 44. Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation 
of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor 
of mutations of EGFR (activating and T790M). Presented at: 2014 
Annual Meeting of the American Society of Clinical Oncology; 2014; 
Chicago, IL.
 45. Kim DW, Lee DH, Kang JH, et al. Clinical activity and safety of HM61713, 
an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer 
(NSCLC) patients (pts) with EGFR mutations who had received EGFR 
tyrosine kinase inhibitors (TKIs). Presented at: 2014 Annual Meeting of 
the American Society of Clinical Oncology; 2014; Chicago, IL.
 46. Janjigian YY, Smit EF, Groen HJ, et al. Dual Inhibition of EGFR with 
Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant 
Lung Cancer with and without T790M Mutations. Cancer Discov. Epub 
July 29, 2014.
 47. Ye X, Zhu ZZ, Zhong L, et al. High T790M detection rate in TKI-naive 
NSCLC with EGFR sensitive mutation: truth or artifact? J Thorac 
Oncol. 2013;8(9):1118–1120.
 48. Walter AO, Sjin RT, Haringsma HJ, et al. Discovery of a mutant-selective 
covalent inhibitor of EGFR that overcomes T790M-mediated resistance 
in NSCLC. Cancer Discov. 2013;3(12):1404–1415.
 49. Cortot AB, Repellin CE, Shimamura T, et al. Resistance to irreversible 
EGF receptor tyrosine kinase inhibitors through a multistep mechanism 
involving the IGF1R pathway. Cancer Res. 2013;73(2):834–843.
 50. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signal-
ing causes resistance to EGFR kinase inhibitors. Cancer Discov. 
2012;2(10):934–947.
 51. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor 
cells: a multifunctional biomarker. Clin Cancer Res. 2014;20(10): 
2553–2568.
 52. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as 
first-line treatment for patients with advanced EGFR mutation-
positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): 
a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 
2011;12(8):735–742.
 53. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent 
iressa versus gemcitabine and cisplatin trial in never-smokers with 
adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128.
 54. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 
947–957.
 55. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-
cell lung cancer harbouring mutations of the epidermal growth factor 
receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet 
Oncol. 2010;11(2):121–128.
 56. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
 57. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group 
in collaboration with Groupe Français de Pneumo-Cancérologie and 
Associazione Italiana Oncologia Toracica. Erlotinib versus standard che-
motherapy as first-line treatment for European patients with advanced 
EGFR mutation-positive non-small-cell lung cancer (EURTAC): 
a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 
2012;13(3):239–246.
